预约演示
更新于：2026-10-12
Pembrolizumab
帕博利珠单抗
更新于：2026-10-12
概要
基本信息
药物类型 单克隆抗体 |
别名 Lambrolizumab、Pembrolizumab (Genetical Recombination)、Pembrolizumab (genetical recombination) (JAN) + [12] |
靶点 |
作用方式 抑制剂 |
作用机制 PD-1抑制剂(细胞程序性死亡-1抑制剂) |
在研适应症 |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (2014-09-04), |
最高研发阶段(中国)批准上市 |
特殊审评加速批准 (美国)、孤儿药 (美国)、优先药物（PRIME） (欧盟)、孤儿药 (日本)、孤儿药 (澳大利亚)、突破性疗法 (中国)、优先审评 (澳大利亚)、优先审评 (美国)、附条件批准 (中国)、优先审评 (中国)、突破性疗法 (美国) |
登录后查看时间轴
结构/序列
Sequence Code 93660H
来源: *****
Sequence Code 93670L
来源: *****
关联
2,753
项与 帕博利珠单抗 相关的临床试验NCT06093425
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating Combination of TST001, Pembrolizumab and Chemotherapy as First-Line Treatment in Subjects With Claudin18.2 Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
NCT04266730
Phase I Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Administered Concurrently With Pembrolizumab
NCT07843550
A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor Monotherapy
100 项与 帕博利珠单抗 相关的临床结果
登录后查看更多信息
100 项与 帕博利珠单抗 相关的转化医学
登录后查看更多信息
100 项与 帕博利珠单抗 相关的专利（医药）
登录后查看更多信息
10,342
项与 帕博利珠单抗 相关的文献（医药）2026-12-31INTERNATIONAL JOURNAL OF HYPERTHERMIA
Focused ultrasound ablation surgery combined with immune checkpoint inhibition in driver-gene wild-type NSCLC with liver metastasis: a feasibility study
Article
作者: Wang, Ting ; Chen, Jinyun ; Ouyang, Bing ; Chen, Li ; Chen, Wenzhi
BACKGROUND:
This single-arm, open-label clinical trial aimed to evaluate the preliminary safety, efficacy and feasibility of focused ultrasound ablation surgery (FUAS) sequential with immune checkpoint inhibitors (ICIs) in patients with driver-gene wild-type non-small cell lung cancer (NSCLC) and liver metastases.
MATERIALS AND METHODS:
Ten eligible patients received two cycles of FUAS sequential with ICIs. The ICIs used include Camrelizumab (7/10), Pembrolizumab (3/10) and Serplulimab used for immune rechallenge (1/10). Follow-up was conducted every 6 weeks ± 3 days, including imaging and hematological assessments. Treatment-related adverse events (AEs) were documented anytime.
RESULTS:
All participants demonstrated stable tolerability and safety in this trial. Immediate post-FUAS ablation rates ranged from 73% to 80%. The median follow-up time is 84 days (IQR, 42-127 days). From baseline to week 18, continuous shrinkage of both hepatic metastatic and target lesions was observed. The DCR of the tumor has reached 80% since the 2nd follow-up (12 weeks), and it remains at 50% until the 4th follow-up (24 weeks).
CONCLUSION:
FUAS sequential with ICIs suggests preliminary safety, activity and feasibility in treating driver-gene wild-type NSCLC patients with liver metastases, further validation is needed.
2026-12-31Human Vaccines & Immunotherapeutics
Durable response of anaplastic thyroid cancer to pembrolizumab combined with chemotherapy: A case report
Article
作者: Zhuang, Yihan ; Chen, Qiongshan ; Lin, Wen ; Chen, Zipei
Anaplastic thyroid cancer is a notoriously aggressive malignancy with a dismal prognosis, typically associated with a median overall survival of less than one year. Therapeutic alternatives are particularly limited for patients without actionable driver mutations. Here, we report a case of BRAF V600E wild-type, PD-L1-positive (tumor proportion score of 80%) anaplastic thyroid cancer with residual/relapsed disease following surgery and subsequent progression on multi-targeted tyrosine kinase inhibitor therapy. The patient was thereafter treated with a combination of pembrolizumab, nab-paclitaxel and carboplatin, resulting in a sustained near-complete response lasting over 30 months, accompanied by a manageable safety profile. The favorable response in this case suggests that further evaluation of this triplet regimen could be considered for anaplastic thyroid cancer, though this remains a speculative premise requiring validation. Further studies are also needed to clarify the underlying mechanisms of this combination and to identify predictive biomarkers for patient selection.
2026-12-31OncoImmunology
A mixed inflammatory peripheral signature defines clinical outcomes in a phase II trial combining pembrolizumab with paclitaxel and carboplatin in melanoma
Article
作者: Cocolakis, Eftihia ; Cailhier, Jean-François ; Lapointe, Réjean ; Thébault, Paméla ; Shechtman, Yelena ; Lepage, Stéphanie ; Letendre, Caroline ; Le, Huy ; Dionne, Jeanne ; Bélanger, Karl ; Jamal, Rahima ; Lambert, Caroline ; Miller Jr, Wilson H.
Checkpoint blockade of PD-1 with pembrolizumab provides long-term survival to a significant proportion of patients with metastatic melanoma. Pembrolizumab has been successfully used in combination with chemotherapy in non-small-cell lung cancer to increase the response rate. This phase II trial combined pembrolizumab with carboplatin/paclitaxel (CP) to assess its safety and efficacy, and to identify correlates of responses. Thirty patients without prior immunotherapy for unresectable/metastatic melanoma were treated with pembrolizumab and CP. Peripheral blood was collected at baseline and after 2 cycles to characterize systemic immune activity by multiplex assays and flow cytometry. Seventy percent of patients received all 4 cycles of CP; 87% received pembrolizumab for 2 y or until progression. Grade 3 and higher adverse events (AEs) occurred in 50% of the patients. The overall response rate (ORR) and disease control rate (DCR) by irRC criteria were 43% and 53%, respectively. Median overall survival (OS) was 23.8 months. Objective response was associated with a lower frequency of naive CD8 T cells and low plasma CCL3 at baseline, along with a larger proportion of mature NK cells and of CD4 T cells expressing BTLA or LAIR-1. Survival rate was higher for patients with lower baseline of IL-6, IL-8, and CD4+CD39+ T cells. Following treatment, pro-inflammatory soluble factors increased in both responders and non-responders. Addition of CP to pembrolizumab in this study did not appear to result in a response or survival advantage and was less tolerable than immunotherapy alone. Correlative data point to peripheral signals to investigate further as potential biomarkers. Trial registration: clinicaltrials.gov, NCT02617849, registered on December 1st, 2015.
100 项与 帕博利珠单抗 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 输卵管癌 | 澳大利亚 | 2026-07-23 | |
| 非肌层浸润性膀胱肿瘤 | 澳大利亚 | 2026-07-23 | |
| 卵巢上皮癌 | 澳大利亚 | 2026-07-23 | |
| 浸润性膀胱癌 | 欧盟 | 2026-07-01 | |
| 浸润性膀胱癌 | 冰岛 | 2026-07-01 | |
| 浸润性膀胱癌 | 列支敦士登 | 2026-07-01 | |
| 浸润性膀胱癌 | 挪威 | 2026-07-01 | |
| 铂耐药性输卵管癌 | 中国 | 2026-06-23 | |
| 铂类耐药性原发性腹膜癌 | 欧盟 | 2026-04-22 | |
| 铂类耐药性原发性腹膜癌 | 冰岛 | 2026-04-22 | |
| 铂类耐药性原发性腹膜癌 | 列支敦士登 | 2026-04-22 | |
| 铂类耐药性原发性腹膜癌 | 挪威 | 2026-04-22 | |
| 铂耐药上皮性卵巢癌 | 欧盟 | 2026-04-02 | |
| 铂耐药上皮性卵巢癌 | 冰岛 | 2026-04-02 | |
| 铂耐药上皮性卵巢癌 | 列支敦士登 | 2026-04-02 | |
| 铂耐药上皮性卵巢癌 | 挪威 | 2026-04-02 | |
| 错配修复缺陷或微高卫星不稳定性结肠癌 | 美国 | 2026-02-10 | |
| 错配修复缺陷或微高卫星不稳定性结肠癌 | 美国 | 2026-02-10 | |
| 肿瘤 | 美国 | 2026-02-10 | |
| 肿瘤 | 美国 | 2026-02-10 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 复发性铂耐药性卵巢癌 | 申请上市 | 美国 | 2025-10-20 | |
| 小肠癌 | 申请上市 | 欧盟 | 2022-03-25 | |
| 非小细胞肺癌Ⅰ期 | 临床3期 | 美国 | 2026-05-04 | |
| 非小细胞肺癌Ⅰ期 | 临床3期 | 日本 | 2026-05-04 | |
| 非小细胞肺癌Ⅰ期 | 临床3期 | 澳大利亚 | 2026-05-04 | |
| 非小细胞肺癌Ⅰ期 | 临床3期 | 巴西 | 2026-05-04 | |
| 非小细胞肺癌Ⅰ期 | 临床3期 | 加拿大 | 2026-05-04 | |
| 非小细胞肺癌Ⅰ期 | 临床3期 | 智利 | 2026-05-04 | |
| 非小细胞肺癌Ⅰ期 | 临床3期 | 哥伦比亚 | 2026-05-04 | |
| 非小细胞肺癌Ⅰ期 | 临床3期 | 法国 | 2026-05-04 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 30 | Pembrolizumab and Carboplatin/ Paclitaxel | 衊顧繭遞廠糧蓋遞餘壓(鬱製觸鬱範壓壓鏇糧鑰) = 餘獵構製窪糧窪憲簾製 壓襯製製繭願淵夢觸遞 (襯鑰積獵淵獵選構繭遞 ) 更多 | 不佳 | 2026-12-31 | ||
临床1/2期 | 难治性经典霍奇金淋巴瘤 PD-1 | 34 | Favezelimab 800 mg plus Pembrolizumab 200 mg | 膚窪襯網簾構廠簾積襯(鹽選鏇獵觸壓製顧鏇蓋) = 1 of 21 participants experienced a dose-limiting toxicity (grade 4 autoimmune hepatitis) 鏇構壓鏇願鑰鏇窪願觸 (艱網夢觸選醖網醖遞壓 ) 更多 | 积极 | 2026-11-01 | |
临床3期 | 1,367 | 廠簾憲鬱願願簾衊願齋(鬱膚鹽夢齋廠選繭醖窪) = 鏇簾繭齋蓋選鑰淵糧遞 鏇積觸膚鏇遞壓鹹範構 (遞簾鏇鑰選築襯鏇蓋蓋 ) 更多 | 积极 | 2026-10-01 | |||
廠簾憲鬱願願簾衊願齋(鬱膚鹽夢齋廠選繭醖窪) = 鏇憲膚艱網艱鹽願製簾 鏇積觸膚鏇遞壓鹹範構 (遞簾鏇鑰選築襯鏇蓋蓋 ) 更多 | |||||||
临床2期 | 25 | Lenvatinib 20 mg po daily + Pembrolizumab 400 mg IV Q6 weeks | 醖鏇鹹廠範夢積艱鬱齋(糧襯蓋膚糧鹹齋糧願鹽) = 繭獵簾淵鹽願繭餘醖襯 製鹹觸糧糧積網衊築積 (遞範構衊窪憲廠夢網獵, 7.8 ~ 35.6) 更多 | 积极 | 2026-10-01 | ||
临床2期 | 非小细胞肺癌 新辅助 | 82 | Pembrolizumab 200 mg + cisplatin-based chemotherapy | 網選願選選鏇積齋餘膚(網鹹餘構憲繭窪憲簾餘) = 淵淵餘鏇艱積築窪鏇壓 鏇蓋繭衊簾鹽醖簾鹹襯 (顧網鹹鏇顧構築糧遞構, 42.8 ~ 74.0) 更多 | 积极 | 2026-10-01 | |
Placebo + cisplatin-based chemotherapy | 網選願選選鏇積齋餘膚(網鹹餘構憲繭窪憲簾餘) = 憲鹹選憲鏇鬱範夢獵廠 鏇蓋繭衊簾鹽醖簾鹹襯 (顧網鹹鏇顧構築糧遞構, 24.8 ~ 53.4) 更多 | ||||||
临床2期 | 78 | (Cohort 1) | 鏇淵獵製淵築廠廠餘襯 = 蓋鹹鏇鑰遞窪觸構網範 製構蓋鹹積鹹糧壓築衊 (鹹簾鹽醖繭憲製壓築蓋, 餘顧鬱願艱顧夢積鬱築 ~ 衊願鏇願構憲鬱夢範窪) 更多 | - | 2026-10-01 | ||
(Cohort 2) | 鏇淵獵製淵築廠廠餘襯 = 製窪選顧憲窪淵製夢觸 製構蓋鹹積鹹糧壓築衊 (鹹簾鹽醖繭憲製壓築蓋, 淵製膚鏇鑰築簾鏇淵遞 ~ 窪獵蓋鏇鹹醖糧壓願醖) 更多 | ||||||
临床1/2期 | 39 | 鏇夢鏇願艱築獵糧網醖 = 壓願鏇鑰簾築範獵壓餘 夢積簾衊醖構廠衊鬱膚 (觸網製衊網艱簾壓繭鹽, 壓範憲廠鹽製選願夢簾 ~ 構糧艱齋網網蓋顧衊觸) 更多 | - | 2026-09-30 | |||
N/A | 1 | 積艱廠觸淵選廠繭選鑰(餘艱鏇醖願遞壓製鹽憲) = 鏇襯遞積選廠壓鏇鏇淵 範鹽網窪膚鑰積膚鬱積 (襯餘網遞積鹹齋壓積齋 ) | 积极 | 2026-09-24 | |||
临床2期 | 48 | 夢醖築蓋襯廠齋淵膚齋 = 鏇鏇廠夢鹽築淵積艱憲 糧構範鏇齋齋鏇壓膚餘 (憲願繭遞廠願糧遞夢襯, 遞餘簾鏇構衊築夢夢膚 ~ 觸製衊廠糧鑰夢窪製構) 更多 | - | 2026-09-22 | |||
临床2期 | 9 | (Arm I (200mg Pembrolizumab 3 Weeks)) | 夢獵鏇願襯顧糧願淵衊 = 鬱衊鑰網鏇衊繭網積壓 範齋遞築構範簾蓋糧醖 (艱廠選鑰觸顧窪選製鏇, 齋壓製蓋蓋衊壓遞餘襯 ~ 齋繭製鏇鑰鏇襯積窪艱) 更多 | - | 2026-09-21 | ||
(Arm II (200mg Pembrolizumab 12 Weeks)) | 夢獵鏇願襯顧糧願淵衊 = 選衊憲顧遞窪夢願膚鬱 範齋遞築構範簾蓋糧醖 (艱廠選鑰觸顧窪選製鏇, 積壓簾淵襯淵衊廠餘夢 ~ 鑰淵膚範選簾獵鏇構齋) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用